drugset / Trial / NCT05610891
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Phase 1
Active not recruiting
50 enrolled
Cellectar Biosciences, Inc.
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).
Timeline
- Start
- 2023-10-01
- Primary completion
- 2026-05
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | I-131-CLR1404 | Small molecule | 10 unknown | Intravenous |
| Subject | I-131-CLR1404 | Small molecule | 20 unknown | Intravenous |